Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment by Dewitte, Heleen et al.
1 
 
Nanoparticle design to induce tumor immunity and challenge the suppressive tumor 
microenvironment 
Heleen Dewitte
1
, Rein Verbeke
1
, Karine Breckpot
2
, Stefaan C. De Smedt
1,*
, Ine Lentacker
1 
 
1
Laboratory for General Biochemistry and Physical Pharmacy, Department of Pharmaceutical 
Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium 
2
 Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Medical 
School of the Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Jette, Belgium 
* Corresponding Author: S.C. De Smedt, Stefaan.DeSmedt@UGent.be, Phone: +32 9 264 80 76 
Fax: +32 9 264 81 89 
  
2 
 
Abstract  
Over the years research in the field of cancer immunotherapy has flourished, bringing about 
crucial breakthroughs, but at the same time revealing new and important pathways of immune 
suppression that put a break on the success of cancer immunotherapy. This review focuses on 
how nano- and micromaterials can be used to induce antitumor immune responses and what their 
role in overcoming immune suppression could be. It is now beyond question that this requires 
elegantly designed particles that can reach their target cells, deliver antigenic cargo and most 
importantly immune stimulants in order to provoke and sustain antitumor immunity.  
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1. Introduction: Cancer immunotherapy on the rise  
The initial idea of exploiting the immune system to combat cancer originated in the early 
1800s, when Dr. Wiliam Coley achieved (limited) antitumor effects by injecting microbe-derived 
toxins [1]. Since then, the field of cancer immunotherapy has evolved drastically, mainly due to a 
number of crucial breakthroughs in our understanding of the complex function of the immune 
system, a number of which are listed in Figure 1.  
 
Figure 1: Timeline overview of important discoveries and milestones that have  
shaped cancer immunotherapy today [2-6]. 
An essential step forward was the identification of dendritic cells (DCs) as the initiators of 
immunity. These cells form a bridge between innate and adaptive immunity by capturing antigens 
and efficiently presenting them to T cells in specialized molecules called major 
histocompatibility complexes (MHCs). Depending on the intracellular location of the antigenic 
protein, presentation will occur either in MHC-I, for cytoplasmic proteins, or in MHC-II for 
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exogenous antigens, which have been endo- or phagocytosed by the cell. Once the antigen-MHC 
complexes are translocated to the DC surface, the presented antigen can be recognized by CD8
+
 
or CD4
+
 T cells in case of MHC-I or MHC-II presentation, respectively. Importantly, these 
antigen-presenting cells (APCs) are unmatched in their capacity to activate naïve antigen-specific 
T cells: DCs are the only cell type that can provide the necessary co-stimulatory signals (e.g. 
ligation of CD86 or CD80 on the DC surface to CD28 on the T cell membrane), chemokines (e.g. 
IP-10 and MIG) and cytokines (e.g. type I IFN and IL-12) required for T cell stimulation. This 
way DCs can initiate proliferation and differentiation of antigen-specific CD8
+
 T cells into 
cytotoxic T lymphocytes (CTLs), and CD4
+
 T cells into helper T cells (Th) [3].  
In the meanwhile, researchers were looking into the Achilles’ heel of tumor cells. For a 
long time, the existence of tumor-associated antigens (TAAs), which are selectively or 
preferentially expressed by tumor cells, was presumed but not proven. As early as 1905, Clowes 
and Baeslack reported that immunity occurred in mice that spontaneously recovered from their 
tumor burden [7]. This was further evidenced by Gross’ experiments in 1943, who proved that 
somehow the immune system of mice was capable of recognizing and rejecting implanted tumors 
[8]. However, it was only in the early 1990s that the first sets of TAAs against which CTL 
responses could be mounted, were actually identified [9, 10]. A timeline review where the 
milestones in TAA discovery and the importance of the choice of TAA for immunotherapy were 
highlighted, was recently published by Coulie et al. [10] 
Taken together, the soft spots of tumor cells and the strengths of our immune system were 
exposed. By combining these novel insights, the road to the development of new therapeutic 
strategies that harness the patient’s immune system to selectively recognize and destroy tumor 
cells was paved. Of note, this review will focus on inducing antitumor immunity by targeting 
DCs. Excellent reviews on other promising strategies in immunotherapy, such as adoptive T cell 
therapy and immune checkpoint blockade, can be found in references [11-13]. 
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2. Inducing antitumor immunity 
2.1. Dendritic cell-based immunotherapy 
The identification of DCs as the initiators of immunity made them interesting targets in 
cancer immunotherapy. Not so long after their discovery, the first report on DC-based 
vaccination was published [14]. In DC-based vaccination, DCs are modified to present TAAs to 
T cells resulting in TAA-specific CTL activation. The production of such cellular vaccines firstly 
requires loading of the DCs with TAAs, after which the cells need to be matured, in order to 
become potent APCs.  
With regards to the antigen-loading of DCs, various strategies have already been explored. 
The earliest studies made use of tumor lysates as a source of antigen. Later on, based on the 
discovery of TAAs, recombinant antigens or antigen-derived peptides were produced and 
passively pulsed into DCs. More recently, researchers have moved on to the use of viral vectors 
for the delivery of DNA or RNA encoding TAAs [15, 16]. Due to safety issues associated with 
the use of these pathogen-based delivery systems, the use of non-viral carriers for the delivery of 
DNA and RNA are currently under investigation.  
After antigen-loading, the DCs are exposed to maturation stimuli. These can be pathogen or 
danger-associated molecular patterns (PAMPs and DAMPs respectively) that can bind to the 
DCs’ pathogen recognition receptors (PRRs) and initiate an intracellular cascade resulting in the 
production of pro-inflammatory cytokines, increased antigen-presentation and augmented 
expression of co-stimulatory molecules (e.g. CD40, CD80, CD86) and chemokine receptors (e.g. 
CCR7). The mature antigen-presenting DCs can then be injected as therapeutic cancer vaccines. 
The initial results were promising, and in 2010, years of research in this field were rewarded by 
the FDA approval of the first DC-based vaccine: Provenge
®
 (Sipuleucel-T, marketed by 
Dendreon) [17].  
Although DC vaccine research is flourishing, a number of important drawbacks hinder the 
applicability of current DC-based vaccines. First of all, and this might even be the most limiting 
factor, all the modification steps described above (i.e. antigen-loading and maturation) are 
performed on isolated cells. This way, the production of these vaccines is labor-intensive. In 
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addition, working with isolated cells makes these therapeutics patient-specific. For every other 
patient, cell isolation, antigen-loading and maturation needs to be repeated, which adds to the 
production costs of the vaccines. Thirdly, it was shown that upon subcutaneous injection of the 
cellular vaccine, DC survival and migration towards the lymph nodes where T cell activation 
occurs, is poor. Merely 5% of the transferred cells are capable of reaching the lymphatics, 
requiring the use of large numbers of antigen-modified cells in order to establish therapeutic 
effects [18]. As a result, only cells that can be isolated in sufficient numbers can be employed. 
For primary plasmacytoid or “conventional” DCs, this is a challenge, therefore researchers have 
chosen for a long time to use monocyte-derived DCs (MoDCs). These cells are obtained by 
isolating a patient’s peripheral blood monocytes (PBMCs) and culturing them with cytokines 
(GM-CSF with or without IL-4) to stimulate their differentiation into MoDCs. These cells, 
however, do not show the same phenotypic properties as most of the lymphoid-resident DCs, but 
rather correspond to “emergency DCs” which are usually only detected at sites of inflammation 
[19]. This, together with loss of activation of the cells once injected, and insufficient cytokine 
production by the in vitro modulated cells, has sparked interest to find ways of loading antigens 
into various circulating DCs subsets in vivo [20, 21].  
2.2. Advantages of particulate systems for DC vaccination in vivo 
The search for in vivo antigen-delivery techniques promptly resulted in the production of 
nanoparticles (NPs) and microparticles (MPs) to carry antigenic material towards DCs in the skin 
or the lymphatics, since the use of particle structures offers many important benefits over the 
delivery of free antigen. Before describing the advantages of particulate vaccines it should be 
noted that a number of prerequisites will determine whether these particulate cancer vaccines are 
indeed able to induce potent immune responses in vivo. 
A first important point is that many novel antigen-delivery systems are still entirely 
evaluated in vitro on murine or human DCs that were generated from bone marrow or blood 
precursor cells, respectively. Indeed, a thorough characterization of the materials with respect to 
their capacity to encapsulate antigen and/or adjuvant, their stability, uptake by DCs and antigen-
transfer to these cells, purely in vitro testing comes with a number of pitfalls. Firstly, it should be 
noted that in vitro generated DCs need to be considered as models for a complex in vivo situation 
where numerous types of DCs exist [22-24]. In addition, for murine DCs, it was reported that 
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slight variations in cell culture protocol resulted in large variation in the phenotype of the 
generated cells, as well as in their capacity to respond to particulate antigen [25]. Moreover, in 
vitro experiments evaluating the particle’s characteristics and uptake by DCs are often 
exclusively performed in serum-free media, making it even more difficult to draw conclusions on 
their in vivo behavior. Therefore, in vitro validation of new carriers should comprise proof of the 
compatibility of the carrier with biological fluids with respect to particle aggregation, size and 
antigen release kinetics. For example, cationic particles are often used for electrostatic binding of 
antigenic protein or nucleic acids encoding antigens. Without additional surface modifications, 
such as grafting polyethylene glycol (PEG) chains on the outer particle surface to provide the 
particle with a hydrophilic shield that reduces the particles’ surface charge, these structures tend 
to quickly aggregate upon contact with serum proteins. This can result in premature antigen 
release and a change in particle size, which leads to different cellular uptake and antigen transfer 
kinetics [26, 27].  
Secondly, the aim of antigen-loaded particles is to deliver the antigenic material to APCs 
for the induction of potent antitumor immune responses. Importantly, evidence emerged 
indicating that potent immune responses can only be mounted when antigens are presented to T 
cells by mature DCs. In fact, where mature DCs stimulate antitumor immunity, antigen-
presentation by their immature counterparts will rather lead to tolerance and suppression of 
effector antigen-specific T cells [28, 29]. The process of DC maturation is complex, finally 
resulting in a complete shift of the cell’s function towards antigen presentation. Thus, fully 
mature DCs are characterized by (a) combined up-regulation of numerous co-stimulatory 
molecules (e.g. CD40, CD80, CD86), (b) cytokine production (e.g. IL-12p70 and IL-6) and (c) 
increased migratory capacities for their translocation to the T cell areas of the lymph nodes. Only 
when all of these processes occur simultaneously are DCs considered as fully mature and are they 
expected to be able to mount potent antitumor immune responses. Thus, an in vivo applicable 
particulate system for DC vaccination should not only deliver antigen, but also exhibit immune 
adjuvant effects and induce complete maturation of the antigen-loaded DCs. Whether NPs and 
MPs as such possess intrinsic adjuvant activity is a recurring topic of discussion. Thorough 
comparisons of the various reports are difficult to make due to the plethora of confounding 
factors (e.g. particle size, surface charge, production methods, additional surface modifications) 
that prevent unbiased conclusion-drawing. Hence, the opinions on carrier-related auto-adjuvancy 
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remain divided: cationic liposomes might induce surface charge density-related DC activation 
[30-32], others show exactly the opposite, pointing towards enhanced adjuvancy of neutral or 
anionic liposomes [33]. Similar debates arose for PLGA capsules, another commonly 
investigated antigen-carrier. Whereas Sharp et al. pointed out that PLGA could induce significant 
cytokine production [34], many other researchers could not observe any PLGA-induced DC 
maturation or cytokine secretion [35]. For most particles, however, it is clear that stimulation of 
DC maturation by including adjuvants will result in the production of more effective particulate 
vaccines. Of note, it was demonstrated that it is crucial to deliver both antigen and adjuvant to the 
same intracellular compartment to obtain both CD4
+
 and CD8
+
 T cell activation [36]. Schlosser 
and colleagues investigated the effect of delivering antigenic protein and adjuvant (CpG 
oligodeoxynucleotides (ODNs), a toll-like receptor 9 (TLR9) agonist or Poly(I:C), a known 
TLR3 agonist) packaged in separate Poly(lactic-co-glycolic) acid (PLGA) microspheres, or co-
formulated within the same microsphere. As expected, co-encapsulation of antigen with a TLR 
agonist significantly improved antigen (cross-)presentation and induction of potent CTL 
responses in vivo [37]. Similar results demonstrating the need for physical association of antigen, 
carrier and adjuvant were obtained for liposomes by Zaks et al. [38]. Therefore, particles should 
be co-formulated with both antigen and PRR agonists (often TLR agonists). In this way, a three-
component system is produced, containing (a) a target antigen, which will direct the immune 
responses towards the cancer cells, (b) an immune potentiator to enhance immune responses 
against the antigen, and (c) a suitable particulate carrier to deliver antigen and adjuvant to the 
DCs at the site of interest.  
Thirdly, choosing a potent adjuvant is crucial, and this could also become a pitfall in 
particle design. For this, it is first of all important to consider that not all TLRs are expressed by 
all DC subsets. Therefore rational design and adjuvant selection based on the subset of DCs that 
will be targeted by the particulate vaccine in vivo are key. Moreover, the cellular location of the 
TLR which is targeted by the adjuvant-particle composite can also play a role. This is 
exemplified by the work of Bal and colleagues, who evaluated liposomal formulations containing 
either Pam3CSK4 (a TLR2-1 agonist) or CpG ODNs (a TLR9 agonist). They observed that the 
delivery of adjuvants to endosomal TLRs, such as TLR3, 7, 8 and 9 benefit more from the 
liposomal delivery than adjuvants to TLRs that are located on the cell surface. As a result, 
liposomal encapsulation of CpG ODNs resulted in prominently better results over liposomal 
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Pam3CSK4 [39]. Furthermore, there are differences in TLR expression on mouse and human DC 
subsets. For instance TLR9, receptor to the popular adjuvant CpG ODNs, is absent on most 
human DC subtypes [40]. Careful and critical interpretation of immunological effects observed in 
mouse models is therefore warranted. An overview of the TLRs, their cellular location and 
commonly used agonists is given in Figure 2. Of note, also other danger-sensing pathways have 
been identified that could be of interest for the development of molecular adjuvants for 
immunotherapy. Potential targets include cytosolic sensors for DNA (e.g. STING) and RNA (e.g. 
RIG-I and MDA-5) and the inflammasome [41, 42].  
 
Figure 2. TLRs on the cell membrane and within the endosomes can ligate to a variety of agonists. By using these 
agonists as immune adjuvants, DC maturation can be induced and antigen-presentation and stimulation of antigen-
specific T cells becomes possible. (TLR = toll like receptor; PAM = Pam3CSK4; MPLA = monophosphoryl lipid A; 
ODN = oligodeoxynucleotide) 
Taking the pitfalls of in vitro-in vivo translation and the requirement for simultaneous 
antigen and adjuvant delivery into account, the following sections will describe the advantages of 
different biomaterials for vaccination purposes, and the different strategies that are used to 
enhance the particulate’s immunogenicity. An overview of different carrier-antigen-adjuvant 
combinations that have been designed and evaluated is listed in Table 1.  
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Table 1: Nanoparticulate carriers for simultaneous antigen and adjuvant delivery to DCs in vivo.  
 
 
Carrier  Particle-related advantages 
Antigenic 
cargo 
Combined immune adjuvants References 
PLGA Antigen release rate can be modified by 
tweaking the ratio of glycolic acid to lactic acid 
Protein CpG ODNs  
Poly(I:C)  
Poly(I:C) combined with resiquimod (R848)  
R848  
[37, 43, 44] 
[37, 43] 
[45] 
[44] 
Tumor 
lysate 
CpG ODNs  [46] 
Peptide MPLA 
CpG ODNs 
[47] 
[48] 
pDNA GpG + IL-10 siRNA 
Poly(I:C) + IL-10 siRNA 
[49] 
[49] 
Liposomes Easy modification and production 
Possible auto-adjuvancy (depending on the 
liposome’s physicochemical properties) [31, 39, 
50] 
Protein MPLA  
non-coding DNA  
CpG ODNs  
Poly(I:C)  
TDB (C-type lectin ligand)  
PAM3CSK4 (PAM) 
Cationic lipid (3,5-didodecycloxybenzamidine, TRX) 
[51] 
[38] 
[38, 39, 52, 53] 
[38, 53, 54] 
[53] 
[39] 
[32] 
Peptide  Non-coding DNA  
CpG ODNs  
Poly(I:C)  
[38] 
[38, 55] 
[38] 
Cubosomes Increased encapsulation compared to liposomes Protein MPLA + imiquimod  [56] 
Gold NPs NP size is easy to control 
Tracking via computed tomography (CT) 
imaging 
Protein CpG ODNs  [57, 58] 
Bacterial 
magnetic 
particles  
Enhanced gene delivery by magnet application  
Auto-adjuvant effects 
pDNA Auto-adjuvant [59] 
Polymeric 
micelles 
High protein loading capacity  
Auto-adjuvant effects 
protein Auto-adjuvant 
Poly(I:C)  
[60] 
[60] 
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2.2.1. Passive DC targeting and the loophole of cross-presentation 
A first advantage of formulating antigens in particles is that by packaging the antigenic 
material in larger constructs, antigens are passively targeted towards phagocytic APCs and can be 
considered for cross-presentation. In general, exogenous antigenic material that is taken up by 
DCs via phagocytosis or endocytosis will end up in the MHC-II presentation pathway, leading to 
the activation of Th cells. Cytoplasmic proteins on the other hand, can be presented in MHC-I 
and result the induction of CTLs. Cross-presentation acts as a loophole in these pathways, 
allowing exogenous antigens to be redirected towards MHC-I. How exactly phagocytosed or 
endocytosed antigens find their way into MHC-I presentation remains vague, although increasing 
evidence demonstrates the involvement of phagosomes, early endosomes and autophagosomes 
[61-63]. By formulating antigens in NPs and MPs, these cross-presentation-competent organelles 
can be targeted, resulting in activation of both CTLs (via MHC-I) and long-lasting memory T 
cells (via MHC-II) [64]. The role of particulate delivery systems in governing antigen-
presentation can be illustrated by the research of Stano et al. They elegantly showed that the use 
of solid-core NPs where antigen is attached to the particle surface, preferentially leads to CD4
+
 T 
cell activation, whereas administration of NPs that encapsulate the antigen within their watery 
core primarily results in CD8
+
 responses. As a result, the authors propose co-administration of 
both antigen-loaded particles since these result in superior immune responses with both CD4
+
 and 
CD8
+
 properties [65]. Additional modifications can be made to nanoparticulate vaccines to 
promote cross-presentation. An example is the inclusion of pH-sensitive polymers into 
liposomes. After endocytic uptake, the reduced endosomal pH will activate the fusogenic 
potential of these polymers, causing disruption of the endosomal membrane and cytoplasmatic 
delivery of the antigenic material. In this way antigen presentation via the MHC-I pathway is 
stimulated and enhanced CTL induction could be achieved [32, 66]. Of course, this specifically 
applies for protein antigen delivery. When antigen-encoding DNA or RNA are delivered, this 
problem completely turns upside down, as the cytoplasmatic protein production upon nucleic 
acid delivery will favor the MHC-I presentation pathway. Here, strategies that target the 
produced antigens to the MHC-II pathway (e.g. via attachment of lysosome-targeting sequences) 
in order to call for T cell help can be applied [67].  
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2.2.2. Protection of antigen integrity and tuning antigen-release kinetics 
Secondly, encapsulating antigens in particles protects them from premature degradation and 
enables modulation of the antigen delivery kinetics. Antigens that are packaged within NPs or 
MPs are shielded from digestive enzymes (proteases and nucleases) that are ubiquitous in blood 
and interstitial fluid. This is especially important for the delivery of nucleic acids (i.e. pDNA or 
mRNA encoding tumor antigens) to DCs, which are much more prone to premature degradation. 
The kinetics of antigen presentation were also shown to exert a major effect on the strength, 
duration and memory of the induced immune responses. For example, Johansen and colleagues 
showed that dose-escalating antigen contact resulted in much stronger CD8
+
 T cell responses 
compared to single-shot antigen delivery [68]. Therefore, particles that result in a burst release of 
the antigenic material upon engulfment by DCs will induce less pronounced immune responses 
compared to sustained release particles. This was evidenced by Demento et al. who compared 
immune response induction by liposomal (fast release) versus slow release PLGA-based protein 
delivery. Indeed, mice vaccinated with liposomes exhibited lower and shorter-lived antibody 
titers and a lower frequency of memory T cells compared to PLGA-vaccinated mice. Similar 
observations were made when slow and fast-release PLGA particles were compared [69]. Thus, 
tweaking the release kinetics of the encapsulated antigen can augment antitumor immunity. As a 
result, clever modifications to basic polymer and liposome structures to ensure longer antigen-
retention and controllable antigen release have been reported. For example, Moon et al. created 
covalent crosslinks between different bilayers of multilamellar liposomes in order to slow down 
the release of antigen [51]. Another considerable option to achieve longer-term antigen 
presentation by DCs is to use nucleic acid-based vaccines instead of protein or peptide vaccines. 
In addition to favoring MHC-I antigen presentation as discussed in 2.2.1., genetic vaccines can 
prolong the duration of antigen presentation and subsequently the activation of CTLs. This was 
demonstrated in a comparative study of Liao et al. where a sustained period of antigen 
presentation was measured after RNA transfection, whereas peptide pulsed DCs rapidly lost their 
ability to present the antigen [70]. Interestingly, the delivery of mRNA have been shown to 
generate more rapid and longer lasting antigen presentation compared to DNA, making mRNA 
an interesting source of antigen [71]. 
 
13 
 
2.2.3. Multifaceted antigen-delivery vehicles 
In addition, particle design is not limited to the mere creation of an antigen-delivery 
structure. NPs and MPs can be equipped with tracer molecules or can be constructed from 
materials that allow in vivo imaging of injected antigen-loaded particles. Imaging and tracking 
the migration of these multifaceted particles from the injection site to the draining lymph nodes 
can provide initial feedback on the vaccine efficacy. For instance, Lee et al. described the 
production of gold NPs that could be covalently loaded with a model protein antigen and CpG 
ODNs. Upon injection of the resulting 23 nm particles in the rear footpads of mice, their 
migration to the popliteal and inguinal nodes could be followed with CT scans [57] . To date 
however, not many research groups have reported on such multimodal particulate vaccines yet. 
The reason for this, is that up to now traceable particles have been mainly designed to determine 
the fate and migratory capacities of ex vivo modified antigen-loaded DCs. The focus on in vivo 
DC targeting is a more recent development in cancer immunotherapy, which gives us reason to 
believe that new multifaceted particles aiming for in vivo modification and migration trafficking 
are expected to follow.  
2.2.4. Alternative biomaterial-based strategies 
Another possibility is to target DCs towards the antigens rather than vice versa. For this, 
Ali and coworkers designed a poly-lactide-co-glycolic (PLG) matrix that releases GM-CSF in 
order to recruit DCs into the scaffold in vivo. Importantly, the authors showed that the number of 
DCs that could be attracted in this way, resembles the amount of ex vivo modified DCs that are 
routinely injected as a cellular vaccine. Upon DC infiltration into the scaffold, the cells can come 
in contact with entrapped tumor lysate as a source of antigen, and CpG ODNs as immune 
stimulants. By fine-tuning the GM-CSF release kinetics from the polymer matrix, the antigen-
loaded mature DCs can be released from the scaffold and migrate to the lymph nodes to allow T 
cell induction [72, 73]. This discovery has lead to the design of alternative immune priming 
centers that aim to attract and in vivo modulate DCs [74]. 
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3. The hurdles of tumor-induced immune suppression 
However promising DC vaccination seemed in the early days, this therapeutic strategy 
failed to live up to the expectations in a clinical setting. Most DC vaccines could increase the 
overall survival by a couple of months with a number of reports describing tumor regression in 
about 15% of patients. Nevertheless, in a high number of patients no effective immune response 
can be induced despite the induction of tumor-specific T cells upon vaccination [21, 75, 76]. In 
part this can be explained by the advanced disease in most patients that were included in DC 
vaccination studies. A more important explanation, which is related to the previous one, is 
immune suppression. Increasing evidence indicates that during tumor development a growth-
supporting micro-environment is created, harboring a plethora of immune suppressive cell types 
which allow the tumor to escape from immune recognition and block effector immune cells at the 
tumor site [77, 78]. Therefore, even if using intelligent antigen- and adjuvant-delivery strategies 
results in the effective proliferation of antitumor CTLs, their recruitment to the tumor or their 
antitumor effector function might be blocked.  
3.1. Mechanisms supporting tumor progression 
When taking a closer look into the tumor microenvironment, the tumor cells themselves act 
as the main mediators of immune suppression. Via different processes, tumors stimulate their 
own growth and deeper tissue invasion. A schematic overview of these mechanisms is given in 
Figure 3. In order to provide nutritional supplements, rapidly growing tumors stimulate 
angiogenesis by secretion of the vascular endothelial growth factor (VEGF). These newly formed 
vessels, however, have larger fenestrae in between the endothelial cells. This results in the 
enhanced permeability and retention (EPR) effect: larger molecules and NPs are capable of 
leaving the circulation and entering the tumor tissue where they are retained due to the reduced 
lymphatic drainage within the tumor tissue [79]. However, neovascularization is often too slow to 
keep up with the rapidly increasing tumor mass, resulting in local hypoxic regions. Especially 
there but even when oxygen is available the growing tumor will increase their glycolytic activity, 
resulting in the accumulation of lactic acid, which reduces the interstitial pH to values of 
generally 7.0-6.6, although values as low as 5.8 have also been reported. This phenomenon of 
“aerobic glycolysis” is known as the Warburg effect [80]. An additional feature of invading 
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tumor cells is their capacity to degrade the extracellular matrix in order to promote deeper tissue 
penetration by producing matrix metalloproteinases (MMPs) [81].  
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Figure 3. The tumor microenvironment. Schematic representation of the soluble and cellular mediators of the 
immune suppressive microenvironment (upper left panel) and how these can be addressed to overcome tumor-
induced immune suppression (upper right panel). Various factors, such as cytokines, secreted by tumor cells create a 
local suppressive milieu in which different immune cells infiltrate and are forced towards an immunosuppressive 
state. These suppressive mechanisms can be generally or specifically addressed to counteract the local tumor-
promoting microenvironment, and (re)activate antitumor immune responses. The lower panel explains the basic 
biochemical changes at the tumor site, and how these can be used to target NPs to the tumor microenvironment. 
(Abbreviations: DC = dendritic cell; TAM = tumor-associated macrophage; MDSC = myeloid-derived suppressor 
cell; Treg = regulatory T cell; TIL = tumor-infiltrating lymphocyte; VEGF = vascular endothelial growth factor; M-
CSF = macrophage colony-stimulating factor; HIF1α = hypoxia-inducible factor 1α; TGFβ = transforming growth 
factor beta; STAT3 = signal transducer and activator of transcription 3; CTL = cytotoxic T lymphocyte; APC = 
antigen-presenting cell; MMP = matrix metalloproteinase; EPR = enhanced permeability and retention) 
Along with these biochemical effects, growing tumors create a local inflammatory 
environment. Already within the early stages of uncontrolled proliferation, infiltration of immune 
cells into the tumor mass has been observed. This can be correlated to the immune surveillance 
theory, which states that the immune system plays a major role in protecting against tumor 
growth. Indeed, the presence of tumor-infiltrating lymphocytes (TILs), mainly antitumor CTLs 
and natural killer (NK) cells within the tumor and in the circulation points are correlated with a 
better patient prognosis, providing evidence for the immune system’s attempt to clear the 
malignant cells [10, 82]. On the other hand the tumor microenvironment is also characterized by 
the prevalence of other immune cells, which will rather support than suppress tumor growth. A 
non-limiting overview of the major mediators of tumor-induced immune suppression is presented 
in Figure 2. Briefly, secretion of inflammatory mediators such as transforming growth factor β 
(TGFβ) by the tumor cells will cause the inactivation of DCs, thus abrogating their capacity to 
efficiently present antigens and induce T cell activation. What is more, suppressive DCs will 
even induce activation of regulatory T cells (Tregs) that counteract CTL responses. Monocytes that 
are attracted into the tumor microenvironment can differentiate into macrophages which either 
promote or counteract tumor growth, depending on the local environment [83]. Although this is a 
gross generalization, M1 polarized macrophages (stimulated by INFγ) are tumoricidal, whereas 
M2 polarized macrophages, also known as tumor-associated macrophages (TAMs, differentiation 
upon encounter of TGFβ, IL-10, IL-4 and IL-13) will stimulate tumor progression. Another major 
mediator of tumor-induced immune suppression are the myeloid-derived suppressor cells 
(MDSCs). These aberrantly differentiated myeloid cells will secrete suppressive cytokines that in 
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their turn block the activity of TILs and induce the expansion of Treg populations. More thorough 
reviews on the different cell types that are present within the tumor microenvironment can be 
found elsewhere [84-86].  
All these soluble factors and suppressive cells help to create a local environment that 
supports tumor growth and counteracts the antitumor effects of activated CTLs and NK cells 
Therefore, finding ways to overcome this tumor-mediated immune suppression and to shift the 
balance back from immune suppression towards immune stimulation could significantly improve 
the immunotherapeutic outcome. Interestingly, many of the immune stimulants that can be used 
to promote the activity of DC vaccines, could also serve as potent adjuvants to modulate 
(suppressed) immunity [87-89]. However, systemic application of these immune activating 
factors generally leads to severe side effects due to unspecific immune activation [90, 91]. Thus a 
more localized approach is warranted. As a result, nano- and micromaterials have been produced 
to locally deliver immune-activating signals in order to shift suppressive cells to an immune 
stimulating phenotype and to overpower immune suppression. The next sections will provide an 
overview of the strategies that can be used to target the tumor microenvironment and which 
particle and adjuvant combinations can target and counteract these different suppressive cell 
types.  
3.2. Particulate systems to overcome tumor-induced immune suppression.  
3.2.1. Targeting the tumor microenvironment 
In order to deliver immunostimulants to different target cells within the tumor 
microenvironment, particulate adjuvants should be able to be directed towards the tumor site, 
deeply penetrate into the tumor tissue and locally deliver their cargo to the target cells. This can 
be made possible by designing NPs that respond to the biochemical differences that exist between 
tumors and neighboring tissues. The different options include (a) making use of the EPR effect 
by controlling NP size; (b) including pH-sensitive materials into nanomaterials; (c) creating 
hypoxia-responsive nanoparticles or (d) including substrates for intratumoral MMPs.  
The EPR effect can be utilized by packaging therapeutics into long-circulating NPs that are 
too large to leave the vasculature in healthy tissue, but that do pass through the larger fenestrae of 
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aberrant neoangiogenic tumor vasculature. Variable pore sizes in solid tumor vasculature have 
been reported, depending on the type of tumor and its localization, but overall, sizes range from 
380 to 780 nm [92]. This means that the ideal NP size to benefit from this EPR effect is likely 
between 10 nm and 400 nm although the upper size range will be tumor-dependent. Indeed, 
different studies have shown selective uptake and drug release into the tumor based on this 
principle. However, the EPR effect only ensures enhanced extravasation and prolonged retention 
of the particles at the tumor site. In order for NPs to reach more distant regions within the dense 
tumor network or to ensure efficient internalization by cells in the perivascular region, additional 
modification strategies are needed. This has resulted in the design of NPs that can extravasate at 
the tumor site where they respond to pH, oxygen levels or MMP presents. As a result, NP 
penetration into the tumor tissue and/or cellular uptake can be promoted. Overall, the benefits of 
utilizing the EPR effect should be addressed with the necessary caution. The main reasons for 
this are the heterogeneity of the EPR effect in different tumors and the limited data that point out 
the advantages of using the EPR effect in humans [93]. 
As a first intratumoral trigger, the decreased intratumoral pH can be exploited. As an 
example, Hu and colleagues produced 35-65 nm cationic micelles that were shielded by PEG via 
a pH-sensitive linker. Thus, in the circulation the PEG corona protects the particles from 
unspecific uptake by phagocytes, whereas at the tumor site, the PEG corona is removed and 
cellular uptake is allowed [94]. It is important to note that the difference in pH between healthy 
tissues (pH 7.4) is usually not that drastically different from the pH in the microenvironment of 
solid tumors (generally around pH 6.6-7.0). Therefore, tumor-targeting particles should be 
designed to already respond to slight differences in pH. Materials that need larger pH differences 
to release their payload or change in conformation could rather serve to enhance cytoplasmic 
delivery upon endosomal acidification, as this occurs at lower pH values. This could then aid in 
avoiding further lysosomal degradation or to promote antigen cross-presentation, as previously 
discussed in section 2.1.1 [95].  
Secondly, the hypoxic tumor microenvironment is characterized by reduced local oxygen 
pressures down to 5-10 mmHg [96]. By incorporating oxygen-sensitive moieties, such as 2-
nitroimidazoles or azobenzene into NPs, hypoxia can be used to trigger PEG-deshielding and 
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enhance cellular uptake of NPs that have reached the tumor site [97] or to provoke drug release 
within the tumor site [98].  
It is important to consider that hypoxia and decreased pH only occur more deeply within 
the tumor. When NPs shrink due to acidic pH or hypoxia in order to allow deeper tumor 
penetration, the NPs should already be able to cover a substantial distance within the tumor 
before they actually encounter their triggers and decrease in size. The increased MMP levels on 
the other hand, are detectable rapidly after extravasation, making this an interesting trigger for 
size-changing NPs. This was elegantly demonstrated by Wong et al, who designed 100 nm 
gelatin particles that can benefit from the EPR effect to be delivered at the tumor site. 
Immediately after extravasation, the gelatin core is degraded by MMP-2 and MMP-9 (both potent 
gelatinases), resulting in the release of smaller 10 nm particles that experience less hindrance 
during their migration through the tumor’s extracellular matrix. This way, delivery deep into the 
tumor tissue could be achieved [99]. Combining multiple tumor-targeting approaches can 
significantly increase the NP’s selectivity towards the tumor. For example, Huang et al. even 
combined three of these tumor-targeting approaches. They reported on a 100 nm polymer NP that 
is equipped with a MMP- and pH-sensitive masked cell penetrating peptide (CPP) for DNA 
delivery. Upon extravasion based on the EPR effect, the reduced intratumoral pH will loosen the 
electrostatic interaction between the CPP and its masking sequence that is cleaved from the CPP 
by MMPs. Thus, the unmasked CPP is free to facilitate cellular uptake and enhance intratumoral 
DNA delivery [100].  
3.2.2. Picking and targeting immune suppressive players within the tumor microenvironment.  
Once NPs can penetrate deeply into tumor tissue, they still need to deliver their therapeutic 
cargo to the target cells of interest. We have previously described which cells play a role in 
sustaining the immunosuppressed tumor microenvironment, and each of them can serve as a 
target to subvert local immune suppression (section 3.1). In the following paragraphs the 
development of a NP toolbox designed to target different cellular components of the suppressive 
microenvironment (summarized in Figure 3, upper right panel) will be highlighted.  
The key initiators of immune tolerance are obviously the tumor cells themselves. They 
secrete immunosuppressive cytokines and a plethora of other factors to sustain their own growth 
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and express ligands on their surface that block the activity of TILs (e.g. programmed death 
ligand-1, PD-L1, which induces CTL apoptosis). Therefore, finding ways to suppress tumor cell-
mediated suppressive mechanisms could tip the balance back towards immune stimulation and 
result in enhanced antitumor effects. An important pathway that mediates immune suppression at 
the tumor microenvironment, is STAT3 (signal transducer and activator of transcription 3) 
signaling. STAT3 mediates tumor growth by – amongst other things – promoting angiogenesis 
and hypoxia, increasing the expression of MMPs and by inducing the secretion of suppressive 
cytokines (e.g. IL-10, IL6, TGFβ) whilst reducing the production of pro-inflammatory cytokines 
(e.g. IL-12, IFNγ, TNF) [101, 102]. Knowledge on the important role of STAT3 has lead to the 
production of NPs that interfere with this pathway, e.g. by delivery of STAT3 siRNA [103]. 
Specific targeting of NPs to cancer cells is possible by incorporating ligands such as folate or 
transferrin. Overall, the number of NPs that address immunotherapeutic targets on tumor cells is 
limited. The reason for this is the genetic instability of transformed cells, which is even more 
pronounced due to the favorable microclimate within the tumor environment. Therefore, tumor 
cells are not such an interesting target as they are capable to rapidly adapt to changed 
circumstances.  
Closely related to the tumor cells, tumor endothelium also acts as a major barrier for TILs 
to reach their target cells [104]. Targeting tumor vasculature is not only interesting to highjack 
the tumor’s oxygen and nutrient supply by delivering anti-angiogenic agents, they can also be 
addressed in light of immunotherapy. An interesting example is the use of CpG ODN-containing 
liposomes which bind to the tumor blood vessels and create a local inflammatory environment. 
This was shown to result in increased numbers of infiltrating CD4
+
 and CD8
+
 T cells into the 
tumor tissue and the induction of antitumor CTLs [105]. Selectively targeting NPs to the tumor 
endothelium is possible by targeting tumor endothelial markers such as the vascular endothelial 
growth factor receptors (VEGF-R) or by using vascular-targeting peptides such as RGR or RGD 
[106].  
As many immune suppressive mechanisms are initiated by intratumoral cytokines, which 
abolish antitumor immunity and promote tumor progression, locally modulating the cytokine 
milieu within the tumor stroma is a therapeutic strategy that can simultaneously tackle multiple 
immunosuppressive mechanisms. Especially TILs and Tregs which are respectively suppressed or 
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induced by the local cytokine environment, are hard-to-reach cellular targets, but their 
functionality can rapidly change by modulating the local cytokine situation. Therefore, packaged 
cytokines that can target the tumor microenvironment and in this way avoid adverse events that 
are typically associated with systemic cytokine delivery, could be powerful immunomodulators. 
Most liposomal or polymeric cytokine-releasing particles (as shown for IL-2 and IL-12) that have 
been designed to date indeed showed significant tumor growth slow-down, however, they did not 
address tumor targeting but were injected intratumorally instead [107-110]. Designing delivery 
systems that can target the tumor microenvironment upon systemic administration, based on the 
principles described in section 3.2.1, could beyond doubt enhance the particle’s applicability. For 
instance, Park and coworkers developed nanoscale liposomal polymeric gels co-encapsulating a 
TGFβ inhibitor and IL-2 that were shown to be delivered to the tumor upon intravenous 
administration. This resulted in an increased NK cell infiltration and a higher CTL-to-Treg ratio, 
which in turn delayed tumor growth and prolonged overall survival in a mouse melanoma model 
[111]. Another strategy could be to even go one step further backwards by opposing two of the 
driving forces of tumor-mediated immune suppression, which steer infiltrating immune cells 
towards a suppressive state: acidosis and hypoxia. This is exemplified by the work of Prasad et 
al. who developed NPs that consume intratumoral H2O2 while producing O2 and increasing the 
local pH from 6.7 to 7.2 [112].  
Recently developed NPs for tumor microenvironment modulation attempt to address 
specific subsets of tumor-infiltrating immune cells. The reasons why these are such interesting 
targets are plural: they are genetically stable, upon activation or re-purposing, their cytokine 
secretion profile changes, which in turn will affect other immune cells that reside in the tumor 
microenvironment. It should first of all be noted that most of the particles that are described 
below generally target the tumor microenvironment. Only in some cases are additional 
modifications made to reach specific cellular targets. As a result, many of these NPs could be 
taken up by various intratumoral immune cells. Moreover, most immunosuppressive cell types 
present within the tumor microenvironment can be stimulated in a similar way, more specifically: 
TLR triggering has beneficial effects on intratumoral DCs, TAMs as well as MDSCs, shifting 
their function towards immune activation and tumor growth suppression [85]. Thus, it is often 
difficult to exactly pinpoint the cells that mediate the observed effects, especially since a 
complete investigation of the effects of a single NP on all mediators of intratumoral immune 
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suppression, was not always performed. Keeping this in mind, NP solutions to tackle different 
cell subsets within the tumor microenvironment will be discussed in the following paragraphs.  
A first specific subset of immune cells that can be steered towards antitumor immunity is the 
intratumoral DC population (Figure 4). Infiltrated DCs can be altered by the tumor microclimate 
to induce T cell anergy or even apoptosis (via PD-L1), stimulate Tregs and to produce 
immunosuppressive cytokines. Thus, there is a major role for NPs in re-educating these 
intratumoral DCs, and re-establishing their antigen-presenting capacities [104]. The particles that 
can be used for this share characteristics to particles for immune induction: they mainly 
incorporate TLR ligands as immune adjuvants to restore their immune activating potential. 
Examples are the use of PEI to complex PD-L1 siRNA to both silence PD-L1 expression and 
resulting CTL apoptosis by DCs while simultaneously utilizing PEI’s TLR5 and TLR7 
stimulatory capacity to activate the cells [113]. Alternatively, Dominguez and Lustgarten 
reported on a 250 nm PLA NP equipped with a tumor-targeting antibody (in this case anti-neu in 
a breast cancer model) as well as with anti-CD40. The latter can ligate to CD40 expressed by 
DCs, macrophages and B cells within the tumor, resulting in the significant up-regulation of pro-
inflammatory cytokines, reduced intratumoral Treg levels and tumor rejection in 70% of the 
animals [114].  
 
Figure 4: Dendritic cells at the tumor microenvironment. Intratumoral DCs can be forced to an 
immunosuppressed state by the local cytokine milieu. As a result, they block CTL activation and even induce CTL 
apoptosis (via PD-1 PD-L1 signaling), activate Tregs and secrete immunosuppressive cytokines (upper right panel). 
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This can be reversed by stimulating DC activation and blocking their suppressive mechanisms (left panel). 
(Abbreviations: CTLA4 = cytotoxic T lymphocyte ligand A) 
TAMs, which represent a rather heterogeneous population of macrophages that reside within the 
tumor, play a crucial part in promoting tumor growth. Most importantly, they protect tumor cells 
from chemotherapeutics, attract Tregs and induce CTL apoptosis. To deal with TAMs, there are 3 
main options, which are summarized in Figure 5 [115, 116]. Firstly, the infiltration of 
inflammatory monocytes and their differentiation into M2 polarized macrophages could be 
inhibited. For this, strategies aiming to reduce the production of chemo-attractants (e.g. 
macrophage colony-stimulating factor, M-CSF) or modulate the suppressive cytokines milieu 
responsible for TAM development (e.g. IL-10 and IL-4) can be used. Currently the number of 
NPs that are specifically designed to address this pathway are limited. They mainly focus on 
sustained release of cytokines within the tumor milieu, as previously discussed. Secondly, it is 
possible to deplete TAMs from the tumor microenvironment, which was shown to restore the 
antitumoral activity of CTLs and lead to tumor growth reduction [117]. A routinely used NP-
based method to selectively deplete TAMs, is the use of liposomal formulations containing 
clodronate or glucocorticoids [118, 119]. Also, Leuschner et al. described a siRNA liposome-
based strategy that prevents the migration of inflammatory monocytes causing a strong reduction 
of TAMs in the tumor site [120]. Lastly and most prominent in current NP research, is finding 
ways to enhance the antitumoral M1 effects of TAMs while blocking their tumor-supporting M2 
effects. Inducing this macrophage switch can be achieved by delivering TLR agonists. Especially 
for the delivery of CpG ODNs (that ligate to TLR9), different delivery vehicles have been 
designed. For instance, gold NPs can be conjugated with CpG ODNs via thiol linkage and 
showed promising cytokine productions in vitro and in vivo [121, 122]. Other groups focused on 
the auto-adjuvant effects of cationic polymers, such as PEI to convert TAMs [123]. However, 
when targeting TAMs, it is important to consider that systemically injected NPs are often subject 
to unwanted clearance by normal macrophages. To avoid this, microenvironment-targeting 
strategies should be employed during particle design. This is exemplified by the work of Huang 
et al. who report on galactosylated cationic dextran particles that are PEGylated via a pH-
sensitive linker to protect the particles against cellular uptake outside of the tumor 
microenvironment, but release them from uptake within the tumor site. There, the presence of the 
galactose moieties allows macrophage targeting, resulting in selective delivery of the CpG ODNs 
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to TAMs. As a result, a phenotypic shift towards M1, reduced neovascularization and reduced 
tumor outgrowth could be observed [124]. Alternative TAM-targeting moieties could be mannose 
and β-glucan (both substrates for the macrophage marker CD206) or folate, since the folate 
receptor β is considered a marker for M2 regulatory macrophages [125].  
 
Figure 5: Tumor-associated macrophages. TAMs are M2 polarized macrophages which suppress immunity and 
promote tumor progression. Their pro-tumor influence can be suppressed by preventing TAM formation from 
infiltrating monocytes, by selectively depleting TAMs or by driving TAMs towards a tumoricidal and 
immunostimulatory M1 macrophage phenotype. (Abbreviations: CCL2 = chemokine (C-C motif) ligand 2; TNFα = 
tumor necrosis factor α; GM-CSF = granulocyte macrophage colony-stimulating factor) 
During cancer development, the differentiation of myeloid cells is altered, promoting the 
existence of a diverse population of pathological MDSCs. Similar to their other suppressive 
accomplices, the main actions of MDSCs to promote tumor progression are impairing CTL 
migration into the tumor, reducing NK cell function, supporting TAM activity and expanding Treg 
populations (Figure 6) [85]. The key to overthrowing their suppressive effects is to force their 
differentiation and maturation into tumor-rejecting monocytes and even functional APCs. 
Although research in the pathways involved in MDSC formation and maturation is still ongoing 
and novel potential targets to deplete MDSCs are being identified [126], successes have been 
obtained via cytokine therapy (local delivery of IL-12 or IFNα) or by the triggering of their TLRs 
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[127]. Once more, CpG ODN-delivering NPs were shown to have potential [122] as well as less 
known particulate adjuvants, such as very small size proteoliposomes (that combine outer 
membrane vesicles from N.meningitidis with a GM3 ganglioside) which were shown to modulate 
myeloid populations within the tumor environment, overcome T cell unresponsiveness and 
reduce tumor growth [128].  
 
Figure 6: Myeloid-derived suppressor cells. MDSCs represent a heterogeneous population of aberrantly 
differentiated myeloid cells that suppress CTL activity, activate and expand Tregs and promote TAM function. Their 
effects can be counteracted by preventing their formation and their infiltration, or by inducing maturation of MDSCs 
into antitumoral monocytes or APCs. 
Once more, we wish to stress that it is very likely that the entire tumor microenvironment 
benefits from modulation of a single suppressed cell subset. By reverting specific cells to a 
(re)activated state, they will for example start producing immunostimulatory cytokines, which 
will likely impact the intratumoral cytokine environment, and could aid to stimulate other 
immune cell subsets as well. On the other hand, and this might become one of the pitfalls in these 
immunomodulation strategies, it should not be forgotten that immune adjuvants can also cause 
adverse effects. First of all, there are the off-site adverse effects, for example when NPs are taken 
up by phagocytic immune cells outside of the tumor microenvironment (e.g. in the liver and 
spleen) or when immune adjuvants are released into the circulation. Therefore, peripheral 
immune activation should always be taken into consideration and delivery strategies need to be 
optimized to restrict the distribution of immune adjuvants to the tumor microenvironment [129]. 
Secondly, there are the on-site off-target adverse effects. This can be illustrated by the 
dichotomous role of TLRs on cancer cells and MDSCs: where short-term high-dose TLR 
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stimulation can result in antitumor immunity, chronic low-grade TLR ligation will rather promote 
tumor growth [130, 131]. 
Overall, tumor-mediated immune suppression is a more recently discovered phenomenon, and 
this also translates in the number of particulates that have been designed to address this problem. 
Especially in comparison to NP vaccines for immune induction, we are still lagging behind in 
addressing the tumor microenvironment. However, we are making important progress. As the 
influence of these immunological accomplices of the tumor cells are now more acknowledged, 
researchers are more and more taking effects of therapeutics on immune cells, instead of 
exclusively on the tumor cells themselves, into account. For example, when She et al. observed a 
drastic improvement in tumor rejection when pixantrone (a topoisomerase II inhibitor) was 
encapsulated within liposomes equipped with sialic acid, they hypothesized that this could very 
well be attributed to TAM killing, as TAMs highly express sialic acid binding receptors on their 
surface [132]. Whether this is indeed the case remains to be investigated, but it already points out 
that looking beyond expected effects on cancer cells and broadening our view to also take a look 
at infiltrating immune cells, could significantly improve novel particulate antitumor therapies. In 
this light, merging established therapies with the exploitation of our immune system could be 
particularly interesting and the development of combination therapies is on the rise.  
4. Combination therapy 
4.1. Immunogenic cell death 
Since Polly Matzinger proposed the “danger model” in 1994, the view on the primary 
occupation of the immune system changed. Where we previously believed that the immune 
system’s basic occupation was to discriminate between “self” and “non-self”, she postulated that 
it is far more concerned with recognizing danger and signs of destruction. In this way, the 
immune system would become activated when it encounters signs of distress, such as cell stress 
or unprogrammed cell death [133, 134]. 
In this regard, it would be crucial for the immune system to be able to distinguish 
programmed cell death, which occurs under normal circumstances, e.g. during embryonic 
development and unprogrammed cell death, which is associated with for instance viral infections. 
27 
 
This was the dawn of “immunogenic cell death”, a process where dying cells become 
recognizable to the immune system by exposing signals that are normally hidden within the cells 
[133, 135]. Over the years, this theory gained support and its validity was evidenced by the 
identification of three key mechanisms that will determine whether cell death can be considered 
as immunogenic [135]. Firstly, the expression of calreticulin (CRT) is normally restricted to the 
endoplasmatic reticulum (ER). However, when the ER experiences stress, CRT is translocated to 
the cell membrane and acts as an “eat-me-signal” activating DCs and macrophages to engulf 
stressed and dying cells. Secondly, stressed cells can release ATP, which again serves as a 
chemoattractant for phagocytic cells. Finally, high-mobility group box 1 (HMGB1), a chromatin 
protein that is expressed by all nucleated cells, can be released. These 3 hallmarks of 
immunogenic cell death were classified as danger-associated molecular patterns (DAMPs). 
Similar to PAMPs (discussed in section 2.1) these patterns will trigger changes within APCs, 
resulting in enhanced antigen presentation and immune stimulation. Moreover, these destroyed 
tumor cells can release TAAs, giving the immune system new targets to combat [136].  
This would mean that inducing tumor cell death in such a way that it becomes 
immunogenic, dying tumor cells could in a way become auto-vaccines by (a) turning tumor cells 
into cellular antigens and (b) exerting adjuvant functions that will trigger the immune system to 
act against released danger signals. Indeed, for various established cancer treatments aiming to 
destroy as much of the tumor tissue as possible, DAMP exposure was detected. For instance 
anthracyclines such as doxorubicine as well as tumor irradiation or hyperthermia results in the 
occurrence of all 3 characteristics of immunogenic cell death [137, 138]. These observations 
paved the way for something that was long thought to be impossible: combining chemo- and 
immunotherapy. For years cytostatic drugs were considered to be detrimental for immunity, as 
toxic effects on lymphocytes are a commonly observed side-effect. Still, studies point towards 
the synergy between TIL reactivation by blocking PD-1 (which suppresses CTL activation) and 
glucocorticoid-induced TNFR related protein (GITR) (which additionally stimulates T cells) and 
chemotherapeutics (paclitaxel or cisplatin) [139-141]. These and other stories of enemies 
becoming allies were recently picked up by material scientists, who packaged these synergistic 
components into single NPs. It should be noted that these combinatorial NPs are still in their 
infancy. In most cases, evidence of their potential is based on in vitro characteristics and 
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biodistribution studies showing their tumor targeting and safety, whereas in vivo results are often 
still underway.  
4.2. Chemo-immunotherapy 
Combination approaches for chemo-immunotherapy both comprise co-delivery of 
cytostatic NPs with adjuvant NPs, as well as the generation of NPs in which both the 
chemotherapeutic drug and the immunostimulant are packaged. Whether or not co-packaging is 
beneficial depends on the nature of the immunostimulants used. In some cases, pre-treatment 
with either the chemotherapeutic or the adjuvant will be preferable, thus requiring the sequential 
delivery of both agents in separate NPs. For example, Su et al. developed TNF-α pDNA 
polyplexes which were delivered 48 h prior to Doxil
®
 (i.e. commercially available stealth 
doxorubicin liposomes). Pre-treatment with the TNF-α pDNA resulted in an increased delivery of 
Doxil
®
 into the tumor, likely due to TNF-α-mediated opening of the tumor endothelial tight 
junctions and enhanced tumor killing in comparison to treatment with each of these NPs alone 
[142]. In contrast, Roy and colleagues focused on co-encapsulating NPs. They conjugated 
paclitaxel to a high-molecular weight sodium phtalate salt of bacteria-derived lipopolysaccharide 
(SP-LPS), a potent TLR4 agonist. These conjugates self-assemble into ~200 nm NPs which upon 
intravenous administration increase the amount of phenotypically mature macrophages and 
activated CTLs into the tumor. More importantly, these conjugate NPs resulted in an improved 
therapeutic outcome compared to each treatment moiety alone [143]. Similar observations could 
be made when paclitaxel was co-encapsulated with SP-LPS into PLGA NPs [144].  
4.3. Thermo-immunotherapy 
In addition to combination with chemotherapeutics, immunotherapy can also be linked to 
thermal ablation of tumors. This therapeutic approach is based on the local cooling (cryo-
ablation) or heating (radiofrequency (RF), high-intensity focused ultrasound (HIFU) or 
photothermal ablation) of cancer tissue. For all these different techniques, immunogenic cell 
death and associated release of DAMPs such as heat shock proteins (HSP) and HMGB1, as well 
as increased immunostimulatory cytokine secretion and infiltration of APCs into the ablated 
regions, was reported [145]. Here too, NPs can be designed aiming to improve the thermal effects 
and simultaneously boost the induced antitumor immunity. Mainly, NPs have been used as nuclei 
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for local heating. In this way, NPs have been developed to deliver thermal energy due to their 
capacity for near infrared (NIR) light absorption (e.g. carbon nanotubes and gold nanoshells) 
[146, 147] or magnetic properties [148]. A recent study by Ito et al. demonstrated that application 
of local hyperthermia using melanoma-targeted magnetite NPs and an external alternating 
magnetic field resulted in a clonal expansion of T cells in B16 tumors [149]. To further enhance 
the immunostimulatory effects of thermal therapies, NPs for photothermal therapy have been 
modified with glycated chitosan (GC) which serves as an immune adjuvant. Indeed, GC inclusion 
resulted in macrophage and DC activation and laser-mediated tumor ablation further increased 
the release of HSP70 and the production of IFNγ, as well as in a significant increase in overall 
survival in a mouse hepatoma model [150]. These first reports indicate that localized 
hyperthermia-based treatments could be enhanced to induce peripheral immunity. In this way 
both the primary tumor (via ablation) and distant metastasis (via immunostimulation) could be 
tackled simultaneously. However, this will require careful optimization of the temperatures that 
should be reached within the tumor to balance destruction of the primary tumor on the one hand, 
and the induction of immunological benefits on the other hand. For example, coagulative ablation 
strategies, where high temperatures “melt” the tumor tissue and completely cut off intratumoral 
blood flow might have the most destructive effect on the primary tumor, but the coagulated tumor 
mass will likely form a barrier for immune cell infiltration and immune induction [146]. More 
thorough comparative studies where multiple immunological parameters are studies are 
warranted.  
5. Conclusions and future perspectives 
Over the last few decades we have come a long way from beginning to understand how the 
immune system protects us from danger and how we can harness it in the battle against cancer. 
By the day our knowledge on effector cells, stimulatory and suppressive cytokine signaling 
pathways and potential therapeutic targets expands. Importantly, integrative strategies that trigger 
antitumor immune responses and simultaneously address tumor-mediated immune suppression 
are on the rise, and these could significantly improve the outcome of clinical trials. Overall, the 
future probably lies in the art of combining: merging established and emerging strategies could 
bring immunotherapy one step closer to the clinic, and it is simply impossible to ignore the rising 
evidence of their synergistic effects. In addition, with what we now know about immunogenic 
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cell death, we could modulate traditional treatment parameters to boost DAMP and antigen 
release, and in this way boost antitumor immune induction.  
Although there still seems to be a gap between these discoveries and the NP solutions that have 
been developed, we are starting to bridge it, as more and more particulate adjuvants, tumor-
targeting strategies and multi-modal vehicles are being designed. Still, nanoparticulate 
immunotherapy remains an underexplored area which could benefit from cross-pollination 
between immunologist and material scientists.  
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